Creating a new therapy using engineered T cells for kidney cancer
Official title: Developing TCR-T cell therapy in renal cell carcinoma
Funded at Rutgers Biomedical and Health Sciences · NIH-11012880 · Data updated 2026-11-12
This study is exploring a new treatment that uses specially designed immune cells to find and kill kidney cancer cells, aiming to give patients with this type of cancer a better option for fighting their disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | January 18, 2024 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $165,145 |
| NIH project number | 5R21CA286389-02 |
| Project ID | NIH-11012880 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with renal cell carcinoma who have specific tumor antigens recognized by engineered T cells.
✕Less likely to help
Patients with other types of cancer or those who do not express the targeted tumor antigens may not benefit from this research.
What this research studies
This research focuses on developing a novel therapy that utilizes engineered T cells to target and destroy kidney cancer cells. By identifying specific tumor antigens that these T cells can recognize, the researchers aim to enhance the immune response against renal cell carcinoma. The approach involves activating tumor-infiltrating lymphocytes (TILs) from patients and testing their effectiveness against cancer cells in the laboratory. If successful, this therapy could provide a new treatment option for patients with this type of cancer.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment for patients with renal cell carcinoma.
How similar studies have gone: Previous research has shown promise in using engineered T cell therapies for various cancers, indicating potential success for this approach in renal cell carcinoma.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Chiou, Shin-Heng — Rutgers Biomedical and Health Sciences
- Study coordinator: Chiou, Shin-Heng
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.